Blood and Urine HPV DNA as Non-Invasive Biomarkers to Detect and Monitor Cervical Cancer After Treatment

What this Trial Is About

Researchers are evaluating if circulating tumor HPV DNA ctHPVDNA in blood plasma and transrenal HPV DNA TrHPVDNA in urine can serve as non-invasive markers to detect and monitor cervical cancer. This study aims to understand the relationship between these DNA levels and the presence of cervical cancer at diagnosis and after treatment. The goal is to improve early detection of recurrence and guide personalized treatment decisions using these biomarkers. Participants diagnosed with cervical cancer will provide blood and urine samples before treatment and again 2 to 6 weeks after completing surgery or chemoradiation. Archived or leftover tissue samples may also be accessed. The study does not involve experimental treatments but focuses on collecting and analyzing biological samples to monitor disease status. During the study, participants will have their plasma and urine tested for ctHPVDNA and TrHPVDNA levels at baseline and post-treatment. Researchers will compare these results to evaluate changes correlated with treatment response. The main outcome is the relationship between these biomarkers and cervical cancer presence. The study will also track changes in these DNA levels following definitive therapy, with participation lasting through the post-treatment sample collection period.

Blood and Urine HPVDNA as Minimally Invasive Biomarkers for Cervical Cancer Detection and Surveillance Following Treatment